Prescient Therapeutics' PTX-100 Shows Promise in Treating Rare and Aggressive Cancer

Prescient Therapeutics' drug PTX-100 has shown promising results in treating Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer. The drug achieved a 64% halt or shrinkage of tumors in Phase 1b trials and maintained a favorable safety profile. PTX-100 has received Orphan Drug and Fast Track designations from the FDA, accelerating its approval process. The company believes PTX-100 could address a broader range of cancers, including lung, ovarian, and pancreatic cancers.

Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has made significant strides in the development of PTX-100, an advanced cancer drug that holds promise for treating Cutaneous T-Cell Lymphoma (CTCL). The company recently reported encouraging results from Phase 1b trials, where PTX-100 demonstrated a 64% tumor halt or shrinkage rate [1].

CTCL, a rare and aggressive cancer, is characterized by its misdiagnosis in early stages and severe side effects. Current treatments have a mixed track record, with 98% of patients experiencing adverse reactions [1]. PTX-100's favorable safety profile, with only one patient reporting a serious side effect (diarrhea), stands in stark contrast to the harsh side effects of existing therapies [1].

The drug has received Orphan Drug and Fast Track designations from the FDA, which accelerates its approval process and provides market exclusivity for seven years post-approval [1]. These designations underscore the potential of PTX-100 to address the significant unmet need in CTCL treatment.

Prescient Therapeutics believes that the technology behind PTX-100 could extend its application to a broader range of cancers, including lung, ovarian, and pancreatic cancers. The company is also advancing its OmniCAR and CellPryme platforms, which aim to enhance the durability and cost-effectiveness of CAR-T treatments [1].

With the number of new cancer cases projected to increase by 77% by 2050, Prescient Therapeutics' drive to innovate and deliver better cancer treatments has never been more urgent or promising [1]. The company's near-term focus is on bringing PTX-100 to a US$1.8 billion market within a few years, while exploring the wider opportunities presented by its other platforms.

References:
[1] https://www.proactiveinvestors.com/companies/news/1074645/prescient-therapeutics-targets-potential-in-cancer-treatment-with-ptx-100-1074645.html